|Bid||168.00 x 800|
|Ask||176.00 x 800|
|Day's Range||173.02 - 175.53|
|52 Week Range||107.59 - 189.00|
|Beta (5Y Monthly)||1.04|
|PE Ratio (TTM)||19.17|
|Earnings Date||Aug 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||207.12|
Jazz Pharmaceuticals' (NASDAQ:JAZZ) stock up by 4.3% over the past three months. As most would know, long-term...
In February, biotech company Jazz Pharmaceuticals (NASDAQ: JAZZ) made some noise when it announced it would acquire GW Pharmaceuticals, a drugmaker specializing in developing cannabidiol (CBD)-derived medicines. The cash-and-stock transaction, which closed in May, was valued at $7.2 billion and represented an almost 50% premium to GW Pharma's market value. While there are good reasons why Jazz Pharma decided to make this move, acquisitions don't always work as planned.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the National Comprehensive Cancer Network® (NCCN) added Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia (ALL), for both pediatric and adult patients.